Gt Biopharma Stock Market Value
| GTBP Stock | USD 2.80 0.24 7.89% |
| Symbol | GTBP |
GT Biopharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.39) | Return On Assets (0.61) | Return On Equity (1.31) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
GT Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to GT Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of GT Biopharma.
| 11/11/2024 |
| 12/11/2024 |
If you would invest 0.00 in GT Biopharma on November 11, 2024 and sell it all today you would earn a total of 0.00 from holding GT Biopharma or generate 0.0% return on investment in GT Biopharma over 30 days. GT Biopharma is related to or competes with Allarity Therapeutics, Neurobo Pharmaceuticals, Virax Biolabs, Quoin Pharmaceuticals, Virpax Pharmaceuticals, Revelation Biosciences, and Biodexa Pharmaceticals. GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immu... More
GT Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure GT Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess GT Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.91 | |||
| Information Ratio | 0.1025 | |||
| Maximum Drawdown | 27.96 | |||
| Value At Risk | (6.23) | |||
| Potential Upside | 8.53 |
GT Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for GT Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as GT Biopharma's standard deviation. In reality, there are many statistical measures that can use GT Biopharma historical prices to predict the future GT Biopharma's volatility.| Risk Adjusted Performance | 0.1007 | |||
| Jensen Alpha | 0.6372 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.1032 | |||
| Treynor Ratio | (4.38) |
GT Biopharma Backtested Returns
GT Biopharma appears to be risky, given 3 months investment horizon. GT Biopharma retains Efficiency (Sharpe Ratio) of 0.13, which attests that the entity had a 0.13% return per unit of price deviation over the last 3 months. By inspecting GT Biopharma's technical indicators, you can evaluate if the expected return of 0.67% is justified by implied risk. Please utilize GT Biopharma's Semi Deviation of 4.41, market risk adjusted performance of (4.37), and Standard Deviation of 4.94 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, GT Biopharma holds a performance score of 10. The company owns a Beta (Systematic Risk) of -0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning GT Biopharma are expected to decrease at a much lower rate. During the bear market, GT Biopharma is likely to outperform the market. Please check GT Biopharma's coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether GT Biopharma's current price history will revert.
Auto-correlation | 0.23 |
Weak predictability
GT Biopharma has weak predictability. Overlapping area represents the amount of predictability between GT Biopharma time series from 11th of November 2024 to 26th of November 2024 and 26th of November 2024 to 11th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of GT Biopharma price movement. The serial correlation of 0.23 indicates that over 23.0% of current GT Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.23 | |
| Spearman Rank Test | 0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
GT Biopharma lagged returns against current returns
Autocorrelation, which is GT Biopharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting GT Biopharma's stock expected returns. We can calculate the autocorrelation of GT Biopharma returns to help us make a trade decision. For example, suppose you find that GT Biopharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
GT Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If GT Biopharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if GT Biopharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in GT Biopharma stock over time.
Current vs Lagged Prices |
| Timeline |
GT Biopharma Lagged Returns
When evaluating GT Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of GT Biopharma stock have on its future price. GT Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, GT Biopharma autocorrelation shows the relationship between GT Biopharma stock current value and its past values and can show if there is a momentum factor associated with investing in GT Biopharma.
Regressed Prices |
| Timeline |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | LLY | Eli Lilly | PairCorr |
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.51 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.